Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

Inclusion Criteria: * 1\. Male patients aged ≥19 years at the time of providing written informed consent. * 2\. Patients with histologically or cytologically confirmed castration-resistant prostate cancer without small-cell features, who have experienced treatment failure with monotherapy of Enzalutamide or Abiraterone. * 3\. Patients with a serum testosterone level \< 50 ng/dL at screening. * 4\. Patients with an increase in PSA compared to baseline, confirmed by two consecutive measurements within 8 weeks prior to the date of written informed consent (with at least 1 week between measurements and an increase of ≥ 50% compared to baseline). * 5\. Patients with PSA levels ≥ 2 ng/mL both prior to the date of written informed consent and at screening. * 6\. Patients with an ECOG performance status ≤ 2 and an expected survival of at least 6 months. * 7\. Patients whose spouse or partner is a woman of childbearing potential must agree to use one of the protocol-specified highly effective methods of contraception from the time of study participation consent until 3 months after the last administration of the investigational product. * 8\. Patients who voluntarily agree to participate in this study and provide written informed consent. Exclusion Criteria: * 1\. Patients who have received chemotherapy, chemoradiotherapy, biologic therapy, immunotherapy, or radiotherapy within 4 weeks prior to the first administration of the investigational product (for docetaxel or cabazitaxel th…